Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10115678 | 1.00 | ESR1 (0.32) | ESR1ESR2 | |
| SCHEMBL13104802 | 1.00 | ESR1 (0.32) | ESR1ESR2 | |
| SCHEMBL13841338 | 1.00 | ESR1 (0.32) | ESR1ESR2 | |
| SCHEMBL6468190 | 0.89 | ESR1 (0.36) | ESR1ESR2 | |
| SCHEMBL21509903 | 0.83 | ALDH1A1 (0.31) | — | |
| SCHEMBL17866987 | 0.82 | ESR1 (0.33) | ESR1ESR2 | |
| SCHEMBL14307889 | 0.80 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL14669294 | 0.78 | NOS3 (0.35) | ESR1ESR2 | |
| SCHEMBL19250250 | 0.77 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL18202440 | 0.77 | ESR1 (0.31) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328225-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-08 | — | — | US | disclosed |
| US-20130029984-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120009141-A1 | FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS | PHARMASCIENCE INC. (CA) | 2012-01-12 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | ESR1 2574/4885ESR2 1755/4885 |
| US-20120009141-A1 | FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS | BIRC5, BIRC7, BIRC2 | ESR1 3961/4885ESR2 4279/4885 |
| US-20130029984-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ESR1 2177/4885ESR2 2260/4885 |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR3 | ESR1 415/4885ESR2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.